多西紫杉醇治疗老年晚期非小细胞肺癌患者的临床分析

目的探讨多西紫杉醇治疗老年晚期非小细胞肺癌患者的临床疗效。方法将2009年8月-2010年7月期间长沙市第一医院收治的老年晚期非小细胞肺癌患者74例随机分成2组。观察组37例，给予单药多西紫杉醇治疗，治疗方案为多西紫杉醇60mg／m2，第1d；对照组37例，给予多西紫杉醇联合卡铂治疗，治疗方案为多西紫杉醇60mg/m2，第1d；卡铂300mg／m2，第1d、第2d；每3周为1个周期。结果两组患者的治疗效果、生存率差异无统计学意义（P〉0．05）。观察组的不良反应发生率显著低于对照组，两组比较差异有统计学意义（P〈0．05）。结论与多西紫杉醇＋卡铂联合方案相比，单用多西紫杉醇治疗老年晚期非小细胞肺癌患者的疗效、生存率相近，但是单用多西紫杉醇的并发症发生率更低，因此目前临床上可以单用多西紫杉醇治疗老年晚期非小细胞肺癌患者。

Clinical Analysis of Docetaxel in Treatment of Elderly Patients with Advanced Non- small- cell Lung Cancer

Objective To explore the clinical therapeutic effect of docetaxel in elderly patients with advanced non-small-cell lung cancer.Methods Seventy-four elderly patients with advanced non-small-cell lung cancer who were admitted into the First Hospital of Changsha City from August 2009 to July 2010 were divided into two groups(n=37).The patients of observation group were received docetaxel 60 mg/m2 on day 1.The patients of control group were given docetaxel combined with carboplatin,and the therapy included docetaxel 60 mg/m2 on day 1 and carboplatin 300 mg/m2 on days 1 and 2.Each treatment cycle of all the patients included 3 weeks.Results There was no statistically significant difference in clinical therapeutic effect and survival rate between observation group and control group(P>0.05).The incidence rate of adverse reactions in observation group was significantly lower than that of control group,and the difference was statistically significant between the two groups(P<0.05).Conclusions Compared with docetaxel and carboplatin combination chemotherapy,single docetaxel has similar clinical therapeutic effect and survival rate,but lower incidence rate of adverse reactions,so docetaxel can be used to treat elderly patients with advanced non-small-cell lung cancer in clinical practice.